Vall d’Hebron Barcelona Hospital
OVERVIEW
The Vall d’Hebron Barcelona Hospital comprises five entities, of which the Institute of Oncology (VHIO) was established in 2006 to conduct research on tumours. In the last 20 years, VHIO has been a point reference in Spain and Europe for personalized medicine in oncology though preclinical, translational and clinical research. One of the institute’s main contributions has been the study of HER2-positive breast cancer positive. For instance, there it was realised the genetic test HER2DX to predict prognosis and drug response to treatment and developed a CAR-T therapy against p95HER protein at a preclinical level.